Trial Profile
A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary) ; Meropenem
- Indications Pyelonephritis; Urinary tract infections
- Focus Adverse reactions
- Acronyms MK-7625A-034
- Sponsors Merck Sharp & Dohme Corp.
- 23 Jan 2023 Results(n=95) assessing Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis published in the Pediatric Infectious Disease Journal
- 10 Dec 2020 Status changed from active, no longer recruiting to completed.
- 17 Nov 2020 Planned End Date changed from 18 Dec 2020 to 3 Dec 2020.